

Molecular Docking and ADME analysis for Anti - HIV1 potential of Quassinoids from *Simarouba glauca*



Sameer Sharma* and Sudhakar Malla

Department of Biotechnology, Indian Academy Degree College, Bangalore, India

Submission: April 30, 2020; Published: May 26, 2020

*Corresponding author: Sameer Sharma, Department of Biotechnology, Indian Academy Degree College, Bangalore, India

Abstract

Objective: The objective of this experiment was to investigate the inhibitory activity of targeted quassinoids from the *Simarouba glauca* employing molecular docking & ADME analysis against selected ligands.

Methods: The 3D structures of ligands were fetched from Pubchem database and subjected to bioinformatics tools such as ADME analysis and Molecular docking simulations to predict the new leads for treatment of HIV-1 infections.

Results: The comparison of molecular docking score exposed that the selected compounds showed better binding affinity towards the known co-crystals. And ADME properties and Lipinski parameters for drug analysis making them potentially momentous agents for Bio-activities. And finally, the results exposed or showed that these selected compounds from *Simarouba glauca* are expected to be beneficial & effective in HIV-1 infections.

Keywords: *Simarouba glauca*; ADME analysis; Lipinski filter analysis; Quassinoids; Anti - HIV1

Introduction

Simarouba glauca has a great history of use in traditional or herbal medicines across the world and mainly the leaf & bark extract of *Simarouba* is best known for its various pharmacological activities like antihelmenthic, antipyretic, anticancerous [1], antiulcer [2], antiamebic, antiprotozoal [3] and many more. The plant includes mainly: ailanthinone, benzoquinone, canthin, dehydroglucarubinone, glaucarubine, glaucarubolone, glaucarubinone, holacanthone, melianone, simarolide, sitosterol, & tirucalla. After discovery of bruceantin (a quassinoid), which is responsible for antileukemic activity, these phyto-molecules gained very much attention [4]. Around 150 quassinoids have been isolated depends on their chemical structures [5]. Considering the future in developing anti-HIV agents with more effective & less harmful compounds, indigenous quassinoids represent a resource of small molecules. The selected quassinoids, some were selected (ailanthinone, benzoquinone, canthin, dehydroglucarubinone, glaucarubine, glaucarubolone, glaucarubinone, holacanthone, melianone, simaroubidin, simarolide, simarubin, simarubolide, sitosterol, & tirucalla) based on PASS prediction server [6]. The given ligands were predicted

to collaborate with both CXCR4 & CCR5. Both of these molecules (CXCR4 & CCR5) are chemokine receptors which are present in different types of cells like macrophages, monocytes, T-cells as well as acts as co-receptor for HIV-1 in these cells. CCR5 was first isolated as a working GPCR which is acted against 3 CC chemokine [7,8]. Among the many CC chemokine that have been noted to bind, CCR5 show the most suppressive activities in HIV-1 infection assays [9] and CCR5 also acts as a potential enhancer despite than an inhibitor of HIV-1 replication [10]. CXCR4 was initially identified as leukocyte-derived seven-transmembrane domain receptor [11-15] but did not get so much response until its isolation as a co-receptor for HIV-1 [16]. Zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, and emtricitabine are potent selective inhibitors ligand and clinically approved by the US and European Union and is nowadays recommended for cure of HIV-1 patients. In the present study, we tried on comparative analysis of the selected quassinoids from the *Simarouba glauca* plant with the known drug and carried out the ADME analysis and molecular docking which investigated the drug likeness of the ligands.

Methodology

Preparation of Ligand

Ligands bind to the protein's binding sites and the SDF (structure data format) files were obtained of all compounds from Pubchem database [17] & analyzed by Marvin view [18]. And then compounds were transformed into 3D structure using PyMol version 1.3 [19]. And physico-chemical properties of the ligands are estimated by Pubchem open chemistry database.

Investigation of drug likeness of the ligands

Lipinski filter were used for drug likeness prediction and according to orally active drug must fulfill some criteria for drug likeness mainly cLogP, molecular mass, hydrogen donor & acceptor, & molar refractive index [20]. And all of these properties were investigated by SWISS ADME, which is noted as a conventional drug discovery tool [21] as well as brain access & gastrointestinal absorption are 2 pharmacokinetic behaviors to measure the various levels of the drug discovery mechanisms. And the Brain or Intestinal Estimated permeation method (BOILED-Egg) is proposed as an exact predictive model [22].

Molecular Docking Analysis

The objective of the molecular docking is to predict the active

binding modes of ligands & orientation of molecules with respect to binding sites. According to this docking, the affinity score gives the ranking of all the binding pores of molecule inside the catalytic site of an enzyme is being done and the targeted compounds were selected for minimization using Ligprep module of Schrodinger. In molecular docking, the receptor grid was analyzed keeping (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, and emtricitabine) on (ailanthinone, benzoquinone, canthin, dehydroglaucaurubine, glaucarubine, glaucarubolone, glaucarubinone, holacanthone, melianone, simaroubidin, simarolide, simarubin, simarubolide, sitosterol, & tirucalla) at the centre of grid with 20 Å edges bearing catalytic sites. Moreover, the molecular docking was performed for given ligands against Protein Data Bank ID using Glide XP 5.8 program [23-25]. After docking, the lowest energy or highest score given by Glide program was selected as the most probable binding pose of top compound.

Results & Discussion

Ligands

(Figure 1 & Table 1) The known drugs exposed polar surface area is around 77 Å²- 135 Å², whereas many selected compounds having less polar surface area like benzoquinone (mass – 108.09 g/mol) followed by canthin, holacanthone, & melianone.

Table 1: Physico-chemical properties of the ligands.

Ligands	Molecular formula	Molecular weight	Monoisotopic mass	Heavy atom count	Topological polar surface area
ailanthinone	C ₂₅ H ₃₄ O ₉	478.53 g/mol	478.220283 g/mol	34	140 Å ²
Benzoquinone	C ₆ H ₄ O ₂	108.09 g/mol	108.021129 g/mol	8	34.1 Å ²
Canthin	C ₁₄ H ₁₀ N ₂	206.24 g/mol	206.084398 g/mol	16	17.8 Å ²
Dehydroglaucarubinone	C ₂₅ H ₃₂ O ₁₀	492.5 g/mol	492.199547 g/mol	35	160 Å ²
Glaucarubine	C ₂₅ H ₃₆ O ₁₀	496.5 g/mol	496.230847 g/mol	35	163 Å ²
Glaucarubolone	C ₂₀ H ₂₆ O ₈	394.4 g/mol	394.162768 g/mol	28	134 Å ²
Glaucarubinone	C ₂₅ H ₃₄ O ₁₀	494.5 g/mol	494.215197 g/mol	35	160 Å ²
Holacanthone	C ₂₂ H ₂₈ O ₉	436.5 g/mol	436.173332 g/mol	31	140 Å ²
Melianone	C ₃₀ H ₄₆ O ₄	470.7 g/mol	470.33961 g/mol	34	59.1 Å ²
Simarolide	C ₂₇ H ₃₆ O ₉	504.6 g/mol	504.235933 g/mol	36	133 Å ²
Sitosterol	C ₂₉ H ₅₀ O	414.7 g/mol	414.386166 g/mol	30	20.2 Å ²
Tirucalla	C ₃₀ H ₅₀ O	426.7 g/mol	426.386166 g/mol	31	20.2 Å ²
Zidovudine (Co-crystal)	C ₁₀ H ₁₃ N ₅ O ₄	267.24 g/mol	267.096754 g/mol	19	134.07 Å ²
Didanosine (Co-crystal)	C ₁₀ H ₁₂ N ₄ O ₃	236.23 g/mol	236.09094 g/mol	17	88.7 Å ²
Zalcitabine (Co-crystal)	C ₉ H ₁₃ N ₃ O ₃	211.22 g/mol	211.095691 g/mol	15	88.2 Å ²
Stavudine (Co-crystal)	C ₁₀ H ₁₂ N ₂ O ₄	224.21 g/mol	224.079707 g/mol	16	78.9 Å ²
Abacavir (Co-crystal)	C ₁₄ H ₁₈ N ₆ O	286.33 g/mol	286.154209 g/mol	21	102 Å ²
Emtricitabine (Co-crystal)	C ₈ H ₁₀ FN ₃ O ₃ S	247.25 g/mol	247.042691 g/mol	16	113 Å ²
Lamivudine (Co-crystal)	C ₈ H ₁₁ N ₃ O ₃ S	229.26 g/mol	229.0521 g/mol	15	113 Å ²




Figure 1: 3D structure of selected ligands & known ligands are a) ailanthinone, b) benzoquinone, c) canthin, d) dehydroglucarubione, e) glaucarubine, f) glaucarubolone, g) glaucarubinone, h) holacanthone, i) melianone, j) simarolide, k) sitosterol, l) tirucalla, m) Zidovudine, n) didanosine, o) zalcitabine, p) stavudine, q) lamivudine, r) abacavir, and s) emtricitabine.

Analysis of Drug Likeness

After completion of Lipinski filter analysis which exposed the

rigidity of all compound to be remembered for structure-based drug design and also listed out the compound's properties with similar to their usage using ADME analysis (Table 2).

Table 2: Lipinski filter analysis.

Ligands	Molecular formula	Hydrogen Bond Donor	Hydrogen Bond acceptor	cLogP	Molar Refractivity
ailanthinone	C ₂₅ H ₃₄ O ₉	3	9	1.34	118.10
Benzoquinone	C ₆ H ₄ O ₂	0	2	0.43	28.29
Canthin	C ₁₄ H ₁₀ N ₂	0	1	2.90	65.26
Dehydroglaucaurbinone	C ₂₅ H ₃₂ O ₁₀	4	10	1.95	121.48
Glaucarubine	C ₂₅ H ₃₆ O ₁₀	5	10	0.32	120.27
Glaucarubolone	C ₂₀ H ₂₆ O ₈	4	8	3.54	99.64
Glaucarubinone	C ₂₅ H ₃₄ O ₁₀	4	10	3.14	126.13
Holacanthone	C ₂₂ H ₂₈ O ₉	3	9	1.78	108.52
Melianone	C ₃₀ H ₄₆ O ₄	1	4	5.18	136.85
Simarolide	C ₂₇ H ₃₆ O ₉	1	9	6.48	117.20
Sitosterol	C ₂₉ H ₅₀ O	1	1	7.19	133.23
Tirucalla	C ₃₀ H ₅₀ O	1	1	7.26	135.14
Zidovudine (Co-crystal)	C ₁₀ H ₁₃ N ₅ O ₄	2	6	-0.14	61.73
Didanosine (Co-crystal)	C ₁₀ H ₁₂ N ₄ O ₃	2	5	0.73	59.22
Zalcitabine (Co-crystal)	C ₉ H ₁₃ N ₃ O ₃	2	3	-0.00	52.62
Stavudine (Co-crystal)	C ₁₀ H ₁₂ N ₂ O ₄	2	4	0.32	54.88
Lamivudine (Co-crystal)	C ₈ H ₁₁ N ₃ O ₃ S	2	4	-0.56	54.46
Abacavir (Co-crystal)	C ₁₄ H ₁₈ N ₆ O	3	6	0.63	84.12
Emtricitabine (Co-crystal)	C ₈ H ₁₀ FN ₃ O ₃ S	2	5	0.00	56.27

Criteria: log P ≤ 5.0, molecular weight in the range of 150–500, H-bond donor's ≤ 5, and H-bond acceptors ≤ 10. The result come from the above table indicates that the ligands selected were

noted to be in acceptable range defined for human use which shows their potential drug like property (Table 3).

Table 3: Admesar analysis.


Ligands	Blood brain barrier	GI absorption	Permeability glycoprotein Substrate	Log S (scale Insoluble < -10<Poorly<-6< Moderately <-4<Soluble<-2Very<0< Highly)[Water solubility]
ailanthinone	No	High	Yes	-3.58 (soluble)
Benzoquinone	No	High	No	-0.48 (very soluble)
Canthin	Yes	High	No	-4.39 (moderate soluble)
Dehydroglaucaurbinone	No	High	No	-4.98 (moderately soluble)
Glaucarubine	No	High	Yes	-2.76 (moderately soluble)
Glaucarubolone	No	High	No	-6.26 (poorly soluble)
Glaucarubinone	No	High	Yes	-4.92 (moderately soluble)
Holacanthone	No	High	No	-3.59 (soluble)
Melianone	No	High	Yes	-6.81 (poorly soluble)
Simarolide	No	Low	No	-8.70 (poorly soluble)

Sitosterol	No	Low	No	-9.67 (poorly soluble)
Tirucalla	No	Low	No	-10.22 (insoluble)
Zidovudine (Co-crystal)	No	High	No	-0.64 (very soluble)
Didanosine (Co-crystal)	No	High	No	-1.85 (very soluble)
Zalcitabine (Co-crystal)	No	High	No	-0.63 (very soluble)
Stavudine (Co-crystal)	No	High	No	-1.33 (very soluble)
Lamivudine (Co-crystal)	No	High	No	-1.27 (very soluble)
Abacavir (Co-crystal)	No	High	Yes	-1.48 (very soluble)
Emtricitabine (Co-crystal)	No	High	No	-1.34 (very soluble)

Brain or Intestinal Estimated permeation method (BOILED-EGG)

The prediction also reveals that Benzoquinone & Holacanthone has high GI absorption followed by known drugs

Zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, and emtricitabine which is then followed by canthin, Dehydroglucarubinone, Glucarubolone have low GI absorption (Figure 2).



Molecular Docking Results

The results obtained from molecular docking of selected compounds with CCR5 & CXCR4 receptors shows that, most of the compounds are exposing better docking score and energy than that known drugs Zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, and emtricitabine which predicts that the compounds taken have the better binding affinity towards the receptor than the co-crystal. And this prediction indicates us to believe that the compounds will be suitable or proper for treatment of HIV-1 infection (Tables 4 & 5). In selected compounds, benzoquinone showed best glide energy in both receptors (-91.34 & -89.37) followed by holacanthone (-87.67 & -85.74), which is far better than the known drugs score and glide energy.

Conclusion

The *in-silico* studies of the selected quassinoid compounds from the *Simarouba glauca* exposed favorable outcomes & the chosen compounds showed better docking score and adme analysis properties than known drugs. Based on ADME prediction Benzoquinone & Holacanthone has high absorption & very soluble compared to co-crystal drugs. The Benzoquinone selected from *Simarouba glauca* are non-toxic. Hence, it has been identified and predicted that all compounds may possibly serve as new leads for the cure of HIV-1 infections and this results might be in future used in *in vivo* studies to test their effects on the cure of HIV-1 infections.

Table 4: Molecular docking simulation with CCR5 co-receptor.

Ligands	Docking score	Glide energy (kcal/mol)
ailanthinone	4816	-78.231
Benzoquinone	4522	-91.345
Canthin	4322	-81.345
Dehydroglaucaurubinone	5310	-79.342
Glaucarubine	4880	-78.917
Glaucarubolone	4018	-67.601
Glaucarubinone	4820	-71.535
Holacanthone	4480	-87.675
Melianone	5456	-80.162
Simarolide	5402	-62.567
Sitosterol	5456	-67.265
Tirucalla	5268	-72.134
Zidovudine (Co-crystal)	5832	-76.111
Didanosine (Co-crystal)	4516	-78.124
Zalcitabine (Co-crystal)	4348	-80.546
Stavudine (Co-crystal)	4012	-81.654
Lamivudine (Co-crystal)	4390	-78.234
Abacavir (Co-crystal)	4044	-89.534
Emtricitabine (Co-crystal)	4610	-76.198

Table 5: Molecular docking simulation with CXCR4 co-receptor.

Ligands	Docking score	Glide energy
ailanthinone	5418	-74.376
Benzoquinone	4416	-89.378
Canthin	4094	-80.435
Dehydroglaucaurubinone	5794	-73.489
Glaucarubine	5394	-77.197
Glaucarubolone	4398	-64.026
Glaucarubinone	5380	-71.404
Holacanthone	4744	-85.748
Melianone	6016	-79.298
Simarolide	5422	-60.869
Sitosterol	5982	-68.476
Tirucalla	6052	-75.101
Zidovudine (Co-crystal)	4048	-76.265
Didanosine (Co-crystal)	4012	-77.876
Zalcitabine (Co-crystal)	4646	-81.321
Stavudine (Co-crystal)	4610	-79.123
Lamivudine (Co-crystal)	4570	-76.435
Abacavir (Co-crystal)	4312	-87.784
Emtricitabine (Co-crystal)	4704	-73.158

References

- Patil MS, Gaikwad DK (2011) A critical review on medicinally important oil yielding plant *Laxmitaru* (*Simarouba glauca* DC.). *Int J Pharm Sci Res* 3: 1195-1213.
- Shankara S, Sriram N (2014) Anti-ulcer activity of *Simarouba glauca* against ethanol and indomethacin induced ulcer in rats. *Int J of Res in pharmacology & pharmaco- therapeutics* 3(2): 85-89.
- Khaling M, Sandeep K, Anand Kumar P, Suresh Kumar, Moirangthem KS, et al. (2014) Comparative in vitro antifungal activities of *Simarouba glauca* against *Fusarium oxysporum* and *Aspergillus parasitic*. *J Med Plants Stud* 2(3): 1-7.
- Kupchan SM, Britton RW, Lacadie JA, Ziegler MF, Sigel CW (1975) The isolation and structural elucidation of bruceantin and bruceantanol, new potent antileukemic quassinoids from *Brucea antidysenterica*. *J Org Chem* 40(5): 648-654.
- Fiaschetti G, Grotzer MA, Shalaby T, Castelletti D, Arcaro A (2011) Quassinoids: From Traditional Drugs to New Cancer Therapeutics. *Curr Med Chem* 18: 316-328.
- Filimonov DA, Lagunin AA, Glorizova TA, Rudik AV, Druzhilovskii DS, et al. (2014) Prediction of the biological activity spectra of organic compounds using the PASS online webresource. *Chem Heterocycl Compd* 50(3): 444-457.
- Combadiere C, Ahuja SK, Tiffany HL, Murphy PM (1996) Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. *J Leukoc Biol* 60(1): 147-152.
- Samson M, Labbe O, Mollereau C, M Parmentier (1996) Molecular cloning and functional expression of a new human CC-chemokine receptor gene. *Biochemistry* 35(11): 3362-3367.
- Blanpain C, Migeotte I, Lee B (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. *Blood* 94(6): 1899-1905.
- Ansari AW, Heiken H, Moenkemeyer M, Schmidt RE (2007) Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. *Immunol Lett* 110(1): 1-5.
- Ederspiel B, Melhado IG, Duncan AM, A Delaney, K Schappert, et al. (1993) Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen. *Genomics* 16(3): 707-712.
- Herzog H, Hort YJ, Shine J, Selbie LA (1993) Molecular cloning, characterization, and localization of the human homolog to the reported bovine NPY Y3 receptor: lack of NPY binding and activation. *DNA Cell Biol* 12(6): 465-471.
- Jazin EE, Yoo H, Blomqvist AG, F Yee, G Weng, et al. (1993) A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. *Regul Pept* 47(3): 247-258.
- Loetscher M, Geiser T, O'Reilly T, R Zwahlen, M Baggiolini, et al. (1994) Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. *J Biol Chem* 269(1): 232-237.
- Nomura H, Nielsen BW, Matsushima K (1993) Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. *Int Immunol* 5(10): 1239-1249.
- Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* 272(5263): 872-877.
- Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. *Asian J of Biotech* 4: 120-128.
- Marvin View (version 18.10.0) (2014) calculation module developed by ChemAxon.
- PyMol - The PyMol Molecular Graphics System, Version 1.3 Schrodinger, LLC.
- Lipinski CA (2005) Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol* 1(4): 337-341.
- Daina A, Michielin O, Zoete V (2017) Swiss ADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* 7: 42717.
- Daina A, Zoete V (2016) A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. *Chem Med Chem* 11(11): 1117-1121.
- Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring 2. Enrichment factors in database screening. *J Med Chem* 47(7): 1750-1759.
- Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. *J Med Chem* 47(7): 1739-1749.
- Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. *J Med Chem* 49(21): 6177-6196.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/JPCR.2020.08.555742](https://doi.org/10.19080/JPCR.2020.08.555742)

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
<https://juniperpublishers.com/online-submission.php>